Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Nov 10;14(8):579–590. doi: 10.1093/procel/pwac056

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

©The Author(s) 2022. Published by Oxford University Press on behalf of Higher Education Press.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 4. — Performance of TEPOC and its combination with CA125 in ovarian cancer subgroups. (A) Endometriosis cohort (endometriosis n = 37 vs. ovarian cancer n = 127), (B) borderline cohort (borderline ovarian tumors n = 43 vs. BAM n = 107), (C) early-stage cohort (early-stage ovarian cancer n = 41 vs. BAM n = 107), and (D) non-epithelial cohort (non-epithelial malignancies n = 23 vs. BAM n = 93). Abbreviations: AUC, area under the curve; TEPOC, tumor-educated platelet-derived gene panel of ovarian cancer; CA125, cancer antigen 125; TEPOC+CA125, a combined diagnosis of TEPOC and CA125; BAM, benign adnexal mass.